Zacks Rating on Qiagen N.V. (QGEN)

Qiagen N.V. (QGEN) has an average broker rating of 2.59, which is interpreted as a Hold, as rated by 11 equity analysts. Nonetheless, 2 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. 1 other analysts advise a Buy. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 2, which is also a Buy. 1 considers that the stock is a Sell.

Qiagen N.V. (QGEN) : 6 investment research analysts covering Qiagen N.V. (QGEN) have an average price target of $24.83 for the near short term. The highest target price given by the Brokerage Firm to the stock is $27 and the lowest target is $22 for the short term. Analysts expect the variance to be within $1.72 of the average price.


Qiagen NV has dropped 0.11% in the last five trading days, however, the shares have posted positive gains of 20.26% in the last 4 weeks. Qiagen NV is up 30.77% in the last 3-month period. Year-to-Date the stock performance stands at -0.4%. Qiagen N.V. (NASDAQ:QGEN): stock turned positive on Tuesday. Though the stock opened at $27.53, the bulls momentum made the stock top out at $27.645 level for the day. The stock recorded a low of $27.47 and closed the trading day at $27.54, in the green by 0.15%. The total traded volume for the day was 648,473. The stock had closed at $27.5 in the previous days trading.

QIAGEN N.V. (QIAGEN) is a Netherlands-based holding company. The Company and its subsidiaries are engaged in providing Sample to Insight solutions that transform biological samples into molecular insights. Sample to Insight solutions are composed of sample and assay technologies, bioinformatics and automation systems. Sample to Insight molecular technologies are applicable across a range of applications and customer classes through more than 500 core consumable products, as well as instruments that automate the use of these products for sample preparation, analysis and interpretation. The Companys bioinformatics solutions connect laboratory workflows and process amounts of genomic data, enabling scientists or clinicians to interpret results and decide on further action.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.